The 16S rRNA sequencing raw data for the study titled Effects of high-dose glucocorticoids on gut microbiota in the treatment of Graves' ophthalmopathy by Xinhuan Su (21147710)

“…The short chain fatty acids (SCFAs)-producing ability in GO patients’ gut after high-dose GCs administration was significantly decreased. The 5-hydroxytryptamine (5-HT) levels significantly increased in gut of GO patients after administering high-dose GCs. …”

Data Sheet 1_Ibrutinib enhances the bias of T cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia.pdf by Fisal Tantoush (20936264)

“…<p>Chronic lymphocytic leukaemia (CLL) is an uncurable haematological malignancy and is associated with significant infection morbidity. Bruton’s tyrosine-kinase inhibitors (e.g., ibrutinib) have improved disease outcomes, but severe infections and poor immunization responses afflict patients. …”

Data Sheet 1_PM2.5 exposure reprograms cell cycle dynamics in uterine immune cells at single-cell resolution.docx by Lin Zhang (8926)

“…Notably, we observed significant changes in immune cell populations, including reductions in macrophages (510 to 58 cells), NK cells (445 to 91 cells), and granulocytes (1597 to 1 cells). …”

Data Sheet 5_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 9_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 6_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 10_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 8_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 1_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 11_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Supplementary file 1_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.xlsx by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 4_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 7_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 3_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Data Sheet 2_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf by Erdengqieqieke Ye (19542808)

“…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…”

Raw data by Jiaxin Wang (21706805)

“…The results of this study indicate that compared to the model group, the content of regulatory enzymes and main products (mainly GCK) of the glycolytic pathway significantly decreased after administration of Rb1, and the key enzyme ACC for fatty acid synthesis also significantly decreased.…”

DataSheet2_D-mannose reduces oxidative stress, inhibits inflammation, and increases treg cell proportions in mice with ulcerative colitis.xlsx by Yuqing Lu (1282527)

“…D-mannose treatment significantly reduced inflammation by decreasing the expression of proinflammatory cytokines and inflammation mediators. …”

DataSheet1_D-mannose reduces oxidative stress, inhibits inflammation, and increases treg cell proportions in mice with ulcerative colitis.pdf by Yuqing Lu (1282527)

“…D-mannose treatment significantly reduced inflammation by decreasing the expression of proinflammatory cytokines and inflammation mediators. …”

PMS repressed ferroptosis in T2DM mice. by Hongmin Zhao (20710544)

“…<p>(a,b) TUNEL staining results demonstrated that the number of cell death in the pancreas of T2DM mice was significantly decreased following PMS intervention. …”

N6-methyladenosine modification of THBS1 induced by affluent WTAP promotes Graves’ ophthalmopathy progression through glycolysis to affect Th17/Treg balance by Lin-na Li (20442989)

“…WTAP was significantly upregulated in CD4⁺ T cells of GO, and WTAP silencing significantly reduced m6A abundance and expression of THBS1. …”